[What is the impact of the new clinical trial data? What are the lessons for patient management?].
Service de Dermatologie & INSERM U895 équipe 1, Hôpital Archet 2, CHU de Nice-BP 3079, Nice, France. passeron@unice.fr
Thierry
T
Passeron
Serge
S
Boulinguez
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001691:Biological Therapy; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003879:Dermatologic Agents / Q000627:therapeutic use; D019468:Disease Management; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D008727:Methotrexate / Q000627:therapeutic use; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data; D011565:Psoriasis / Q000188:drug therapy / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D035703:Therapies, Investigational; D016896:Treatment Outcome; D000069549:Ustekinumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D000069285:Infliximab; D000069549:Ustekinumab; D000068879:Adalimumab; D000068800:Etanercept; D008727:Methotrexate